Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCX872-B + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- ChemoCentryx
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CCX872-B + FOLFIRINOX is a combination regimen used in clinical trials for the treatment of advanced or metastatic pancreatic cancer. **CCX872-B** is a selective oral small molecule antagonist of the chemokine (C-C motif) receptor 2 (CCR2), designed to inhibit migration of immunosuppressive myeloid cells into the tumor microenvironment and thus enhance antitumor immune responses. **FOLFIRINOX** is a multi-agent chemotherapy regimen consisting of four intravenously administered drugs: folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin. The rationale behind this combination is that blocking CCR2-mediated recruitment of suppressive immune cells can improve the efficacy of cytotoxic chemotherapy with FOLFIRINOX. The regimen has been studied in phase Ib clinical trials for pancreatic cancer, where it showed promising progression-free survival, objective response rates (ORR), and overall survival (OS) with an acceptable safety profile. CCX872-B is developed by ChemoCentryx.
- Other names
- CCX872-B and FOLFIRINOXCCX-872-B and FOLFIRINOXCCX 872-B and FOLFIRINOXCCX872 plus FOLFIRINOXCCX-872 plus FOLFIRINOXCCX 872 plus FOLFIRINOXCCX872 + FOLFIRINOX
02
Targets
TOP1 (DNA Topoisomerase I)DHFR (Dihydrofolate reductase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on CCX872-B + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCX872-B + FOLFIRINOX.